bismuth has been researched along with paclitaxel in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brechbiel, MW; Kelly, MP; Lee, FT; Scott, AM; Smyth, FE; Tahtis, K | 1 |
1 other study(ies) available for bismuth and paclitaxel
| Article | Year |
|---|---|
Radioimmunotherapy with alpha-particle emitting 213Bi-C-functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy.
Topics: Alpha Particles; Animals; Antibodies, Monoclonal; Antineoplastic Agents, Phytogenic; Apoptosis; Bismuth; Cell Line, Tumor; Combined Modality Therapy; Female; Humans; Immunoglobulin Fab Fragments; Isothiocyanates; Lewis Blood Group Antigens; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Nude; Paclitaxel; Pentetic Acid; Radioimmunotherapy; Radioisotopes; Survival Rate; Tissue Distribution; Xenograft Model Antitumor Assays | 2007 |